Project Details
Description
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
| Acronym | ILLUMINATE-C |
|---|---|
| Status | Finished |
| Effective start/end date | 21/01/20 → 1/07/25 |
Collaborative partners
- Alnylam Pharmaceuticals (lead)
- Dubai Health Authority
Keywords
- PH1
- Primary Hyperoxaluria
- Hyperoxaluria
- RNAi Therapeutic
- siRNA
- AGT
- Systemic Oxalosis
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carbohydrate Metabolism Inborn Errors
- Metabolism Inborn Errors
- Inborn Genetic Diseases
- Metabolic Diseases
- Renal Agents
- Lumasiran
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.